CD24 and cancer: In conclusion, there remains significant untapped potential in the development of CD24 antibody drugs, and we believe there is an urgent need to find the unique glycosylation pattern in cancer cells in order to design antibody drugs targeting this specific site of CD24, which will require concerted efforts to develop effective antibody drugs.